Select Page

Internet Billionaire Sean Parker Behind First CRISPR Test

MIT Technology Review had some interesting news to break today: the first proposed test of CRISPR gene-editing technology in human beings is being funded by none other than Internet billionaire Sean Parker, the well-known cofounder behind Napster and first president...

Gene Editing Causing Challenges for EU Policymakers

After a quarter century of conflict over genetically modified foods, it’s understandable that initial reactions to gene editing—the technical process of editing or removing specific genes of an organism—being applied to produce and livestock have been met with...

Intellia Therapeutics Raises $108M in Upsized IPO

Novartis-backed, preclinical upstart Intellia Therapeutics ($NTLA) announced May 6th that it’s going for the top range of its IPO, selling 6 million shares at $18 a share to raise a total of $108 million. Founded in 2014, Intellia quickly caught the attention of...

Evaluating Debt When Investing in Biotech

Biotech companies pour millions of dollars into research programs every year, but the outcome is never guaranteed. The money used to fund this research can, in part, come from issuing stock or taking on debt. How much debt should be a concern for investors. Debt...

Biotech’s Next Innovation: Lab-Grown Meat

The biotech industry has some of the most interesting/bizarre trends you’ll find when researching investment opportunities. From prosthetic limbs to gene editing, biotechnology pushes the limits of what could be every day. One of the latest interesting trends to...